NCT02306993Active, not recruiting
Sickle Cell Hemoglobinopathies and Bone Health
Sickle Cell Hemoglobinopathies and Bone Heath
Source: ClinicalTrials.gov · Last updated 24 Aug 2026
Brief summary (registry, in English)
This research study has two purposes. The first purpose is to determine whether having sickle cell trait (SCT) is a risk factor for the development of bone thinning at an earlier age than expected. Nearly 10% of African Americans (AA) carry sickle cell trait and most of them are unaware of it. African Americans are less likely to develop thin bones than whites, but if they sustain a bone fracture, they are more likely to die from it. We believe having sickle cell trait may lead to bone thinning and predispose a subset of African Americans to dangerously thin bones. The second purpose is to try to understand why individuals with sickle cell disease (SCD) have thinner bones than healthy individuals do. Doctors have already discovered that people with sickle cell disease have very thin bones, but they have not determined why. Our study will try to identify whether the bone thinning is from the body not making enough bone or from the body losing bone once it is made.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 45 (estimated)
- First submitted
- 1 Dec 2014
- Start date
- 1 May 2014
- Primary completion date
- 30 Nov 2028
- Lead sponsor
- UConn Health
- Diseases
- Sickle cell disease
- NCT number
- NCT02306993
What you commit to
- Study type: Observational
- Planned participants: 45
- From 1 May 2014 to the primary completion date, 30 Nov 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Taking oral contraceptives or medications known to influence bone metabolism (e.g. Glucocorticoids, anti-resorptive or anabolic medications for osteoporosis, pharmacologic Vit D dosing).
- Taking an investigational drug.
Other illness
- Known metabolic bone disorder (e.g. uncontrolled thyroid disease, hyperparathyroidism).
Other
- Pregnant, breast-feeding, or within 3 months post-partum.
Who the study is looking for
- Age 18-45 years.
- Female.
- Regular menstrual periods.
- Self-identification of African American race.
Age in the registry: 18 years to 45 years · Sex: Female · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| UConn Health Coordinator of this site? Confirm its status | Farmington | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.